Review my approach to CAR T-cell therapy—including considerations for patient candidacy and managing toxicities—illustrated with a patient case from my practice.
In this commentary, Matthew J. Frigault, MD, highlights key studies of CAR T-cell therapy that will be presented at the upcoming 2019 ASH annual meeting in Orlando.
Read expert answers to audience questions from a recent symposium on current best practices and emerging directions in CAR T-cell therapy.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.